New drug combo targets tough cancers with KRAS mutation
NCT ID NCT05194995
First seen Mar 19, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests a combination of two drugs, JAB-21822 and cetuximab, in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. The goal is to see if the combo is safe and can shrink tumors. About 48 adults who have already tried at least one standard treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research site01
Beijing, Beijing Municipality, 100101, China
-
Research site02
Beijing, Beijing Municipality, 100101, China
-
Research site05
Zhengzhou, Henan, 450000, China
-
Research site06
Harbin, Heilongjiang, 150000, China
-
Research site07
Zhengzhou, Henan, 450000, China
-
Research site08
Nanchang, Jiangxi, 330000, China
-
Research site09
Nanjing, Jiangsu, 210000, China
-
Research site11
Changsha, Hunan, 410000, China
-
Research site12
Beijing, Beijing Municipality, 100101, China
-
Research site13
Nanning, Guangxi, 530021, China
-
Research site16
Linyi, Shandong, 276002, China
-
Research site18
Wuhan, Hubei, 430079, China
-
Research site19
Hangzhou, Zhejiang, 310005, China
-
Research site23
Xi’an, Shanxi, 710000, China
-
Research site28
Shanghai, Shanghai Municipality, 200032, China
-
Research site29
Changsha, Hunan, 410000, China
-
Research site31
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.